Imcivree Guideline

May be approved for members who meet all of the following criteria:
- Diagnosis is for chronic weight management due to obesity
- Age is at least 6 years or older
- Obesity is defined by one of the following:
  - For age 18 years or older
    - Body Mass Index (BMI) greater than or equal to 30 kg/m²
  - For age less than 18 years
    - Body Mass Index (BMI) greater than or equal to 95th percentile for age on growth chart assessment
- Documentation of genetic testing demonstrating deficiency of homozygous variants, or compound heterozygous variants, to one of the following genes:
  - Proopiomelanocortin (POMC)
  - Proprotein convertase subtilisin/kexin type 1 (PCSK1)
  - Leptin receptor (LEPR)
- Documentation that gene variants of proopiomelanocortin (POMC), or proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) are interpreted as pathogenic, likely pathogenic, or of uncertain significance
- Medical records indicating baseline Body Mass Index (BMI) and member weight
- Submission of growth chart for ages less than 18 years

All other indications are considered experimental/investigational and not medically necessary

Duration of Approval if Requirements Are Met:

Initial Approval:
6 months

Renewal Approval:
12 months

Requires:
- For members receiving less than 12 months of therapy, one of the following must be met:
  - At least 5% of baseline body weight was lost
  - Body Mass Index (BMI) reduction was by at least 5% from baseline and member has continued growth potential
- For members receiving 12 months or more of therapy:
  - Achieved or sustained clinically meaningful weight loss

1 Imcivree References:

Current Version Effective: 10.1.2022